Q BioMed Inc. Prices $5.5 Million Public Offering

Proceeds To Fund Commercialization of First Approved Drug and Pivotal Clinical Programs in 2018 NEW YORK, January 30, 2018 /PRNewswire/ Q BioMed Inc. (OTCQB: QBIO) ( Q BioMed or the Company ), a commercial stage biotechnology acceleration development company is pleased to announce pricing of a public offering of an aggregate of 1,711,875 shares of common stock of the Company, together with warrants to purchase up to 1,711,875 shares of common stock of the Company, at a public offering price of $3.20 per share
http://bit.ly/2rQE15I